Source: Owler

XVIVO Perfusion AB: XVIVO's revenue changed from $53.19M in Sep 2023 to $59.22M in Dec 2023

XVIVO’s Trailing Twelve Months revenue changed from $53.19M in Sep 2023 to $59.22M in Dec 2023 increasing 11.3% in this time period.

Read full article »

XVIVO Perfusion AB's Competitors | XVIVO Perfusion AB's News | XVIVO Perfusion AB's Financials

Followers on Owler

Annual Revenue

$25-100M

Employees

100-250

CEO

Christoffer Rosenblad

CEO Approval Rating

82/100

XVIVO is a Sweden-based medical technology company that develops optimized solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation.